The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 4, Pages 377-382
Publisher
Informa UK Limited
Online
2016-03-05
DOI
10.1586/14737140.2016.1162099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- How I treat the older patient with acute myeloid leukemia
- (2014) G. Ossenkoppele et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice
- (2013) Martin S. Tallman et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
- (2013) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse
- (2012) J. V. Malfuson et al. ANNALS OF HEMATOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association
- (2011) Hassan Farhat et al. AMERICAN JOURNAL OF HEMATOLOGY
- Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
- (2011) U. Brunnberg et al. ANNALS OF ONCOLOGY
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?
- (2011) Maciej Bogdan Maniecki et al. LEUKEMIA RESEARCH
- Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
- (2010) B. Lowenberg et al. BLOOD
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902
- (2010) Richard M. Stone et al. LEUKEMIA RESEARCH
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin
- (2009) P Chevallier et al. LEUKEMIA
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia
- (2008) Patrice Chevallier et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now